Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBITDA (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed EBITDA for 7 consecutive years, with -$8.4 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA rose 44.25% year-over-year to -$8.4 million; the TTM value through Mar 2026 reached -$49.7 million, up 19.41%, while the annual FY2025 figure was -$56.3 million, 11.64% up from the prior year.
  • EBITDA hit -$8.4 million in Q1 2026 for Barinthus Biotherapeutics, up from -$11.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $13.2 million in Q2 2022 and bottomed at -$30.9 million in Q4 2024.
  • Average EBITDA over 5 years is -$11.5 million, with a median of -$13.6 million recorded in 2023.
  • Year-over-year, EBITDA surged 230.71% in 2022 and then tumbled 2180.43% in 2023.
  • Barinthus Biotherapeutics' EBITDA stood at -$25.1 million in 2022, then soared by 62.5% to -$9.4 million in 2023, then plummeted by 228.6% to -$30.9 million in 2024, then surged by 64.54% to -$11.0 million in 2025, then grew by 23.71% to -$8.4 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$8.4 million, -$11.0 million, and -$17.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.